News

Researchers have shown that reducing inflammation in the brain could potentially protect against memory and behavioural changes linked with the progression of Alzheimer’s disease, raising hopes of a new treatment pathway for the condition. 

GSK, Pfizer and Shionogi venture ViiV Healthcare is linking with Janssen Sciences Ireland to develop and commercialise the first long-acting, two-drug injectable treatment regimen for HIV.

Teva UK has launched its fertility treatment Ovaleap in the UK, offering a biosimilar alternative to Merck Serono’s Gonal-f.

The US Food and Drug Administration has agreed to review Regeneron and Sanofi’s biologic sarilumab as a treatment of rheumatoid arthritis.

Almost one in five patients are forced to wait a week or more to see a GP, the latest GP Patient Survey results have revealed.

Roche and C4 Therapeutics have formed a strategic collaboration to develop novel treatments in the field of targeted protein degradation, in a deal potentially worth $750 million. 

Novo Nordisk is seeking approval from the European Medicines Agency to market its long-acting haemophilia B therapy nonacog beta pegol.

As many as 700,000 new cases of cancer linked to being overweight or obese could be diagnosed during the next 20 years, warns a new report from Cancer Research UK and the UK Health Forum.

The Care Quality Commission has appointed the first National Guardian for whistleblowers in the NHS, in the hope fostering an environment that encourages healthcare workers to speak up over sub-standard care.

Merck & Co has signed a deal with Quartet Medicine to advance the biotech’s investigational, first-in-class pain treatment and potentially buy the company for $575 million.

There are warnings that general practice in England is on the verge of collapse as an investigation by the BBC reveals a growing number of practices are being forced to close their doors to new patients because of “immense pressures”.

Patients in Wales with certain forms of colorectal cancer will now get restricted access to Merck’s Erbitux on the National Health Service. 

Industry observers believe MannKind could be facing bankruptcy after Sanofi handed back rights to the inhaled insulin Afrezza, following its lacklustre performance on the market.

Bristol-Myers Squibb has hooked up with French biotech Oncodesign to discover develop and commercialise novel macrocyclic compounds for cancer and other serious illnesses with no known effective treatment.

Lilly has issued lower than anticipated financial guidance for 2016, with projected profits and revenues below analysts’ expectations.